Researchers have achieved a monumental leap in the efficiency and stability of inkjet-printed quantum-dot light-emitting diodes (QLEDs) by employing a pressure-assisted thermal annealing (PTA) technique, which enables the acquisition of highly ordered quantum-dot (QD) thin films via inkjet printing. This innovative approach has propelled QLEDs to unprecedented external quantum efficiency (EQE) over 23%, signaling a significant step toward the mainstream adoption of this display technology.

Centrosomes are nonmembrane organelles and responsible for microtubule nucleation and organization. Centrosomal RNAs have been identified in diverse model systems and are known to regulate gene expression during cell division in many species. However, whether and how centrosomal RNAs exist in C. elegans and, if yes, their functions and mechanisms remain unclear. A recent study published in SCIENCE CHINA Life Sciences explored the potential presence and biogenesis of peri-centrosome localized small interfering (si)RNAs in C. elegans by utilizing the nuclear RNAi Argonaute protein NRDE-3 as a reporter. The findings suggest that the peri-centrosomal region may serve as a platform for RNAi-mediated gene regulation, offering new insights into centrosomal (si)RNAs.

Researchers from the School of Metallurgy and Environment at Central South University, together with their collaborators, have proposed a novel buried interface strategy for stabilizing zinc anodes. The zincophilic Sn layer is buried under the corrosion-resistant ZnS layer (SZS), which effectively solves the dendrite formation and corrosion problems. The zinc anodes coated with SZS exhibit significantly enhanced cycling stability and long-term performance. This buried interface engineering strategy offers a promising avenue for the rational design of zinc anodes in rechargeable batteries, potentially advancing energy storage technology.

A landmark review in Molecular Biomedicine outlines cutting-edge strategies to combat tuberculosis (TB), highlighting novel vaccines, AI-driven antigen discovery, and next-gen therapies to address drug-resistant strains and improve global TB control.